Category Archives: "INforMS"

The FDA approves a generic form of Copaxone
The FDA Approves a Generic form of Copaxone® Thursday, April 16, 2015 The U.S. Food and Drug Administration has approved a generic [...]
People with multiple sclerosis may have trouble recognizing emotions
People with MS may have trouble recognizing emotions -- MS can damage parts of the brain that allow us to recognize emotions in others. [...]
EMA validates marketing authorization application for ZINBRYTA for treatment of multiple sclerosis
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTAâ„¢ (Daclizumab High-Yield Process) for Treatment of [...]
Teva Neuroscience & Access Health team up for special multiple sclerosis awareness show: thursday, 3/5
Teva Neuroscience & Access Health Team Up for Special MS Awareness Show: Thursday, March 5 As Multiple Sclerosis Awareness Week [...]
Multiple sclerosis paroxysmal symptoms confused with seizures due to sudden onset
Multiple sclerosis paroxysmal symptoms can be confused with seizures due to its sudden onset. Paroxysmal symptoms are unique to multiple [...]
How Vitamin D repairs myelin in multiple sclerosis
An international team of researchers have proposed how vitamin D repairs myelin in multiple sclerosis. This finding could lead to [...]
Acorda announces data from first clinical trial of remyelinating antibody in multiple sclerosis
Acorda Announces Safety and Tolerability Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis Phase 1 trial [...]
First multiple sclerosis patients in the U.S. receive Genzyme’s Lemtrada following FDA approval
First MS Patients in the U.S. Receive Genzyme’s Lemtrada Following FDA Approval – Lemtrada now available in the U.S. two weeks post [...]
Genzyme’s Lemtrada approved by the FDA
Genzyme’s Lemtrada Approved by the FDA - Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows [...]
Genzyme announces enrollment of first patient in phase II Vatelizumab trial in RRMS
Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis Tuesday, November [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM